Why a Migraine Guidelines Closed Forum?
The objective of this international meeting – MGF – is to better understand guidelines development process and its implications in clinical practice and for patients’ empowerment.
It is not to develop new guidelines, but to gather a multidisciplinary panel of leading international experts to discuss the latest evidence, on-going research, controversial issues and pending questions that have implications for the development of clinical practice guidelines.
All around the world, many chronic diseases – such as Migraine – are a burden for health systems and their management still needs to be much improved. Conversely, the success and failure stories that inevitably accompany the release of new guidelines may be a source of inspiration for further research and development; ultimately, guidelines really shape clinical practice if healthcare professionals and their patients adopt them.
Accordingly, the process of guidelines elaboration needs critical improvements because of the lack of knowledge and adherence of industrial companies, healthcare professionals, patients’ associations and patients themselves to their best practice recommendations. A better understanding of the processes involved in guidelines development and dissemination will help companies that develop drugs, biomarkers, technology, radiology and medical devices, to adapt and improve their research and development programs for the future. This could also translate into earlier and more efficient development of diagnostic and therapeutic tools for Migraine patients.
That is why TMA has built an innovative model for creating a mandatory space of discussion on guidelines in major therapeutic fields. The TMA Guidelines Forums have been created in order to discuss their development process and successful implementation for a better management of unmet healthcare needs.
How do guideliners deal with the available evidence and what are their expectations in this respect? What criteria must a product or an intervention meet to be recommended by migraine guidelines? What are the most frequent reasons for migraine ? Why may guidelines of geographically distinct origins but dealing with the same evidence occasionally reach different conclusions? What should be done to avoid that guidelines being lost in translation?
Speakers and discussants who will address these topics have been selected from among the top-level European experts who participate in the regular update of guidelines. The faculty also comprises clinicians with a strong interest in translational and patient-centered medicine.
The Migraine Guidelines Close Forum will be strictly academic – meaning that attendees will not participate during the main sessions and discussions. However, they will be able to transmit written questions to the faculty.
Without any doubt, the Migraine Guidelines Close Forum is a rare opportunity.
Don’t miss it!
- Individual registration
- TMA proposes three levels of potential sponsorship for this FORUM:
- Platinum Sponsorship: Up to 5 attendees at the Forum; acknowledgment at the Forum as Platinum Sponsor; 1 case based discussion during the Forum, Video highlights disseminated to 5 000 healthcare providers,1 Satellite Symposium at 2018 major meeting to disseminate the conclusions of the Forum: 150 K€.
- Gold sponsor: Up to 5 attendees at the Forum, recognition as Gold Sponsor, 2 case based discussions during the forum, video highlights disseminated to 5 000 healthcare providers: 50 K€.
- Silver sponsor: Up to 3 attendees at the Forum, recognition as Silver Sponsor, 1 case based discussion during the Forum healthcare providers with logo: 25 K€.
Contact us to finalize your participation as sponsor
Event coordinator :
Grant Opportunities (including CME, Advisory Boards & Customized Grants)
William Melhuish / Yann Colardelle
Tel.: + 33 (0) 6 16 54 81 57
E-mail: firstname.lastname@example.org and email@example.com
For individual attendees’ registration contact TMA : firstname.lastname@example.org